| Detected | Trial | Change |
|---|---|---|
| 2026-05-23 | NCT07271667 A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in… |
Trial sites expanded: 3 -> 7 locations |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 2 | |||
| NCT07271667 | A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in… | Chronic Lymphocytic Leukemia | Recruiting |
| NCT05564390 | MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study… | Acute Myeloid Leukemia | Recruiting |
| NCT07463820 | A Trial Comparing Three Different Treatment Options for Adults With Low-Risk… | Myelodysplastic Syndrome | Not Yet Recruiting |
| Phase 1/2 | |||
| NCT03328078 | CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in… | Relapsed Hematologic Malignancy | Recruiting |
| Phase 1 | |||
| NCT07107750 | Emavusertib (CA-4948) in Combination With Cisplatin, Gemcitabine, and Durvalumab in… | Metastatic Biliary Tract Cancer | Recruiting |
| NCT05187182 | CA-4948 in Combination With FOLFOX/PD-1 Inhibitor +/- Trastuzumab for Untreated… | Gastric Cancer | Recruiting |
| NCT06439836 | Pembrolizumab Plus CA-4948 for the Treatment of Patients With Progressive Metastatic… | Metastatic Urothelial Carcinoma | Recruiting |
| NCT06696768 | Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With… | Metastatic Colorectal Adenocarcinoma | Recruiting |